
MBB1: Breast Tumour Tissue Array (Human)






Description

| Product code | MBB1 |
|--------------------|--|
| Cases | 129 |
| Row number | 18 |
| Column number | 9 |
| Core diameter (mm) | 0.6 |
| Thickness | 4μm |
| Tissue array type | FFPE |
| Species | Human |
| Application | Immunohistochemistry |
| | In situ hybridization |
| | Fluorescent in situ hybridization |
| | Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) analysis In situ polymorase chain reaction (In situ PCP) |
| | in situ polymerase cham reaction (in situ PCK) |
| Notes | Storage temperature : 4°C Shipping temperature : Ambient |
| Notes | In situ polymerase chain reaction (In situ PCR) |

TMA map:



| Position | Age | Gender | Pathology diagnosis | TNM | Grade | Type of tumour |
|----------|-----|-----------------|--------------------------------|---------------|-------|----------------|
| A1 | | | | | | |
| A2 | 45 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
| A3 | 53 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| A4 | 42 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant |
| A5 | 35 | F | Invasive ductal carcinoma | T2/T1b N0 MX | 3 | Malignant |
| A6 | 58 | F | Invasive ductal carcinoma | T3 N3 MX | 2 | Malignant |
| A7 | 65 | F | Invasive ductal carcinoma | T2/T1b N1a MX | 2 | Malignant |
| A8 | | | | | | |
| A9 | 55 | F | Invasive ductal carcinoma | N/A | 2 | Malignant |
| A10 | 51 | F | Invasive ductal carcinoma | T2 NX MX | 3 | Malignant |
| A11 | 53 | F | Invasive ductal carcinoma | T3/T1c N2a MX | 3 | Malignant |
| A12 | 67 | F | Invasive lobular carcinoma | T1b NX MX | 2 | Malignant |
| A13 | 51 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| A14 | | | | | | |
| A15 | 45 | F | Invasive ductal carcinoma | T3 N3 MX | 3 | Malignant |
| A16 | 60 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| A17 | 54 | F | Invasive ductal carcinoma | T2 NX MX | 2 | Malignant |
| A18 | | | | | | 1 - 1 |
| B1 | | | | | | |
| B2 | 40 | F | Invasive ductal carcinoma | T2 N2a MX | 2 | Malignant |
| B3 | 56 | F | Invasive ductal carcinoma | T1c N2a MX | 3 | Malignant |
| B4 | 57 | F | Invasive ductal carcinoma | T3 NX MX | 3 | Malignant |
| B5 | 82 | F | Invasive ductal carcinoma | T2 N3 MX | 3 | Malignant |
| B6 | 62 | F | Invasive ductal carcinoma | T1c N1a MX | 2 | Malignant |
| B7 | 70 | F | Invasive ductal carcinoma | T2 N0 MX | 2 | Malignant |
| B8 | 70 | | invasive adetai caremonia | 12 10 10// | _ | Wangnane |
| B9 | 49 | F | Invasive ductal carcinoma | T1c NX MX | 3 | Malignant |
| B10 | 47 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant |
| B11 | 69 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| B12 | 61 | F | Invasive ductal carcinoma | T1c NX MX | 3 | Malignant |
| B13 | 55 | F | Invasive ductal carcinoma | T1c NX MX | 3 | Malignant |
| B14 | 33 | 1 | invasive dactar caremonia | TECHNIVIA | | ivialignant |
| B15 | 49 | F | Invasive ductal carcinoma | T2 NX MX | 2 | Malignant |
| B16 | 55 | F F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| B17 | 41 | <u>'</u> F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| B18 | -47 | ' | mivasive ductal calcillottia | 12 140 1417 | | ividiigiialit |
| C1 | | | | | | |
| C2 | 53 | F | Invasive ductal carcinoma | T2/T1c N2a MX | 2 | Malignant |
| C3 | 62 | F | Invasive ductal carcinoma | T2 NX MX | 3 | Malignant |
| C4 | 48 | F | Invasive ductal carcinoma | T1c N1a MX | 3 | |
| | 61 | F | | | 3 | Malignant |
| C5 | | F | Invasive lobular carcinoma | T1c NX MX | 1 | Malignant |
| C6 | 51 | F F | Invasive ductal carcinoma | T1c N0 MX | 3 | Malignant |
| C7 | 70 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| C8 | 40 | - | Investiga diretal as of the or | T1 - NO NAV | 1 | Maliera |
| C9 | 49 | F | Invasive ductal carcinoma | T1c N0 MX | 3 | Malignant |
| C10 | 36 | F | Invasive ductal carcinoma | T2 N1 MX | 3 | Malignant |
| C11 | 71 | F | Invasive ductal carcinoma | T2 N1 MX | 3 | Malignant |

| C12 | 38 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
|-----|-----|---|------------------------------|---------------|---|---------------|
| C13 | 60 | F | Invasive ductal carcinoma | T4b N1a MX | 3 | Malignant |
| C14 | 100 | ' | invasive ductar caremonia | 146 IVIA IVIA | | Ivialignant |
| C15 | 57 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| C16 | 56 | F | Invasive ductal carcinoma | T3 N2a MX | 3 | Malignant |
| C17 | 36 | F | Invasive ductal carcinoma | T1c N0 MX | 3 | Malignant |
| C18 | 30 | | invasive ductar caremonia | 11E NO IVIX | 1 | Ivialignant |
| D1 | | | | | | |
| D2 | 61 | F | Encysted papillary carcinoma | T2 N0 MX | 2 | Malignant |
| D3 | 38 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| D4 | 51 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| D5 | 68 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant |
| D6 | 51 | F | Invasive ductal carcinoma | T1c N1 MX | 2 | Malignant |
| D7 | 81 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
| D8 | | | | | | |
| D9 | 66 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| D10 | 62 | F | Invasive ductal carcinoma | T1c N0 MX | 3 | Malignant |
| D11 | 47 | F | Invasive ductal carcinoma | T2 N3c MX | 3 | Malignant |
| D12 | 40 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| D13 | 53 | F | Invasive ductal carcinoma | T4b N3a MX | 3 | Malignant |
| D14 | | • | mvasive daetai earemema | 110110011111 | | - Iviangriani |
| D15 | 42 | F | Invasive ductal carcinoma | T2 N1 MX | 2 | Malignant |
| D16 | 67 | F | Invasive ductal carcinoma | T2 N1c MX | 2 | Malignant |
| D17 | 71 | F | Invasive ductal carcinoma | T1c N0 MX | 1 | Malignant |
| D18 | , = | | mrasive daetai caremonia | 12011011111 | - | - Wangilani |
| E1 | | | | | | |
| E2 | 64 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| E3 | 41 | F | Invasive ductal carcinoma | T4b N2a MX | 3 | Malignant |
| E4 | 76 | F | Invasive ductal carcinoma | T1c N0 MX | 3 | Malignant |
| E5 | 33 | F | Invasive ductal carcinoma | T1c N1a MX | 3 | Malignant |
| E6 | 43 | F | Invasive ductal carcinoma | T4b N3a MX | 2 | Malignant |
| E7 | 63 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| E8 | | | | | | |
| E9 | 57 | F | Invasive ductal carcinoma | T1c NX MX | 3 | Malignant |
| E10 | 41 | F | Invasive ductal carcinoma | T3 N1 MX | 3 | Malignant |
| E11 | 54 | F | Invasive ductal carcinoma | N/A | 3 | Malignant |
| E12 | 56 | F | Invasive ductal carcinoma | T2 NX MX | 3 | Malignant |
| E13 | 49 | F | Invasive ductal carcinoma | T2 NX MX | 3 | Malignant |
| E14 | | | | | | |
| E15 | 71 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
| E16 | 63 | F | Invasive ductal carcinoma | T4b N2a MX | 2 | Malignant |
| E17 | 42 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| E18 | | | | | | |
| F1 | | | | | | |
| F2 | 48 | F | Invasive ductal carcinoma | T2 N0 MX | 2 | Malignant |
| F3 | 44 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
| F4 | 59 | F | Invasive ductal carcinoma | T2 NX MX | 3 | Malignant |
| F5 | 49 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |

| F6 | 47 | F | Invasive ductal carcinoma | T2 N2a MX | 2 | Malignant |
|-----|------|-----|----------------------------|------------|---|-----------|
| F7 | 51 | F | Invasive ductal carcinoma | T4b N3a MX | 2 | Malignant |
| F8 | | | | | | |
| F9 | 40 | F | Invasive ductal carcinoma | T1c NX MX | 3 | Malignant |
| F10 | 67 | F | Invasive ductal carcinoma | T3 NX MX | 3 | Malignant |
| F11 | 61 | F | Invasive ductal carcinoma | T3 N2 MX | 3 | Malignant |
| F12 | 56 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant |
| F13 | 52 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| F14 | | | | | | |
| F15 | 48 | F | Invasive ductal carcinoma | T2 N1 MX | 2 | Malignant |
| F16 | 63 | F | Invasive ductal carcinoma | T2 N3a MX | 3 | Malignant |
| F17 | 51 | F | Invasive lobular carcinoma | T2 N2a MX | 2 | Malignant |
| F18 | | | | | | |
| G1 | Mark | ker | | - | | - |
| G2 | 58 | F | Invasive ductal carcinoma | T2 N2 MX | 2 | Malignant |
| G3 | 54 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
| G4 | 53 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| G5 | 46 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant |
| G6 | 61 | F | Invasive ductal carcinoma | T1c N0 MX | 3 | Malignant |
| G7 | 59 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| G8 | | | | | | |
| G9 | 49 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| G10 | 51 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| G11 | 59 | F | Invasive ductal carcinoma | T1c N1a MX | 3 | Malignant |
| G12 | 72 | F | Invasive ductal carcinoma | T1c NX MX | 2 | Malignant |
| G13 | 50 | F | Invasive ductal carcinoma | T2 N2 MX | 2 | Malignant |
| G14 | | | | | | |
| G15 | 68 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant |
| G16 | 60 | F | Invasive ductal carcinoma | T1c N1a MX | 2 | Malignant |
| G17 | 67 | F | Invasive ductal carcinoma | T2 N2 MX | 2 | Malignant |
| G18 | 52 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| H1 | Mark | er | | _ | | |
| H2 | 62 | F | Invasive ductal carcinoma | T4b N1 MX | 2 | Malignant |
| Н3 | 35 | F | Invasive ductal carcinoma | N/A | 2 | Malignant |
| H4 | 70 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| H5 | 79 | F | Invasive ductal carcinoma | T2 N2a MX | 3 | Malignant |
| H6 | 30 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| H7 | 68 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| H8 | | | | | | |
| H9 | 40 | F | Invasive ductal carcinoma | T4b N2a MX | 3 | Malignant |
| H10 | 46 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| H11 | 56 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant |
| H12 | 56 | F | Invasive ductal carcinoma | T1c N2 MX | 3 | Malignant |
| H13 | 58 | F | Invasive ductal carcinoma | T4b N0 MX | 2 | Malignant |
| H14 | | | | | | |
| H15 | 47 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant |
| H16 | 50 | F | Invasive ductal carcinoma | T1c N1a MX | 3 | Malignant |
| H17 | 60 | F | Invasive ductal carcinoma | T2 N3a MX | 2 | Malignant |
| H18 | 59 | F | Invasive ductal carcinoma | T2 NX MX | 2 | Malignant |

| l1 | Marker | | | | | | |
|-----|--------|---|---------------------------|------------|---|-----------|--|
| 12 | 66 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant | |
| 13 | 44 | F | Invasive ductal carcinoma | T1c N1a MX | 2 | Malignant | |
| 14 | 43 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant | |
| 15 | 55 | F | Invasive ductal carcinoma | T1c N2a MX | 3 | Malignant | |
| 16 | 63 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant | |
| 17 | 68 | F | Invasive ductal carcinoma | T4b N1a MX | 2 | Malignant | |
| 18 | | | | | | | |
| 19 | 45 | F | Invasive ductal carcinoma | T2 NX MX | 2 | Malignant | |
| I10 | 55 | F | Invasive ductal carcinoma | T2 N1a MX | 3 | Malignant | |
| l11 | 48 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant | |
| l12 | 52 | F | Invasive ductal carcinoma | T4b N3a MX | 3 | Malignant | |
| l13 | 55 | F | Invasive ductal carcinoma | T2 NX MX | 2 | Malignant | |
| l14 | | | | | | | |
| l15 | 54 | F | Invasive ductal carcinoma | T1c N1a MX | 3 | Malignant | |
| I16 | 65 | F | Invasive ductal carcinoma | T1c N0 MX | 2 | Malignant | |
| 117 | 64 | F | Invasive ductal carcinoma | T2 N0 MX | 3 | Malignant | |
| I18 | 38 | F | Invasive ductal carcinoma | T2 N1a MX | 2 | Malignant | |

Stage description

The American Joint Committee on Cancer (AJCC) TNM system is the frequently employed breast cancer staging system, and it is based on seven important elements:

- The extent (size) of the tumor (T): How large is the cancer? Has it grown into nearby areas?
- The spread to nearby lymph nodes (N): Has the cancer spread to nearby lymph nodes? If so, how many?
- The spread (metastasis) to distant sites (M): Has the cancer spread to distant organs such as the lungs or liver?
- Grade of the cancer (G): How much do the cancer cells look like normal cells?
 - Estrogen Receptor (ER) status: Does the cancer have the protein called an estrogen receptor?
 - **Progesterone Receptor (PR) status:** Does the cancer have the protein called a progesterone receptor?
 - **HER2 status:** Does the cancer make too much of a protein called HER2?

Tumor (T)

T1: Tumour ≤ 20 mm in greatest dimension.

T1a: Tumor > 1 mm but \leq 5 mm in greatest dimension (round any measurement >1.0-1.9 mm to 2 mm).

T1b: Tumor > 5 mm but ≤ 10 mm in greatest dimension

T1c: Tumor > 10 mm but ≤ 20 mm in greatest dimension

T2: Tumour > 20 mm but \leq 50 mm in greatest dimension.

T3: Tumour > 50 mm in greatest dimension.

T4: Tumor of any size growing into the chest wall or skin. This includes inflammatory breast cancer.

T4a: Extension to chest wall, not including only pectoralis muscle adherence/invasion

T4b: Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange)

of the skin, which do not meet the criteria for inflammatory carcinoma.

T4c: Both T4a and T4b.

T4d: Inflammatory carcinoma.

Nodes (N)

NX: Nearby lymph nodes cannot be assessed.

NO: No regional lymph node metastasis identified histologically.

N1: Micrometastases; or metastases in 1-3 axillary lymph nodes and/or in internal mammary nodes; and/or in clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy.

N1a: Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm).

N1b: Metastases in ipsilateral internal mammary lymph nodes, excluding ITCs, detected by sentinel lymph node biopsy

N1c: Combination of N1a and N1b

N2: Metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases.

N2a: Metastases in 4-9 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm).

N2b: Metastases in one or more internal mammary lymph nodes, causing them to become enlarged.

N3: Any of the following:

N3a: Metastases in \geq 10 axillary lymph nodes (at least 1 tumor deposit > 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes.

N3b: Metastases in at least one axillary lymph nodes (at least 1 tumor deposit > 2.0 mm) and has enlarged the internal mammary lymph nodes; or metastases in 4 or more axillary lymph nodes (at least 1 tumor deposit > 2.0 mm) and in the internal mammary lymph nodes on sentinel lymph node biopsy.

N3c: Cancer has spread to the lymph nodes above the collarbone (supraclavicular nodes) on the same side of the cancer with at least one area of cancer spread greater than 2 mm.

Metastasis (M)

 $\boldsymbol{\mathsf{M0}}\xspace$. No clinical or radiographic evidence of distant metastasis .

M1: Any histologically proven metastases in distant organs; or if in non-regional nodes, metastases > 0.2 mm.

Mx: Distant metastasis cannot be assessed.